Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences director Jacqueline K. Barton received equity compensation on April 30, 2026. She was granted 1,146 restricted stock units that vested immediately, each representing one share of common stock, bringing her direct holdings to 27,202 shares. She also received a non-qualified stock option for 4,884 shares at an exercise price of $130.84 per share, with all option shares vesting immediately and expiring on April 30, 2036.
Gilead Sciences director Sandra Horning reported new equity compensation awards. She received 1,146 restricted stock units under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, with each RSU representing one share of common stock and vesting immediately on April 30, 2026.
She was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, which vested 100% on April 30, 2026 and expires on April 30, 2036. Following these awards, she directly holds 6,293 shares of Gilead common stock.
Gilead Sciences director Ted W. Love received new equity awards as part of his compensation. On April 30, 2026, he was granted 1,146 restricted stock units under the 2022 Equity Incentive Plan. Each RSU represents one share of common stock and vested immediately on the grant date.
On the same date, he was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, with all shares under the option vesting immediately and expiring on April 30, 2036. Following these awards, he directly holds 5,484 common shares and 4,884 options.
Gilead Sciences director Javier Rodriguez received new equity awards as part of his compensation. He was granted 1,146 restricted stock units, each representing one share of common stock, which vested immediately on April 30, 2026, raising his direct common stock holdings to 13,364 shares.
Rodriguez was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share. All of these option shares vested immediately on April 30, 2026 and are scheduled to remain exercisable until April 30, 2036.
Gilead Sciences director Anthony Welters reported equity awards rather than open-market trades. On April 30, 2026, he received 1,146 restricted stock units that each convert into one share of common stock and vested immediately. He was also granted 4,884 non-qualified stock options with a $130.84 exercise price, which fully vested on the grant date and are exercisable until April 30, 2036. Following the RSU grant, his direct common stock holdings totaled 12,894 shares.
Gilead Sciences director Harish Manwani reported routine equity compensation and related tax withholding. He received 1,146 restricted stock units, which vested immediately and increased his direct common stock holdings to 15,239 shares after the grant.
He also received a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, fully vested on April 30, 2026 and expiring in 2036. Separately, 224 shares were withheld at $130.84 per share to cover tax obligations, a non‑market, tax-withholding disposition rather than an open-market sale.
Gilead Sciences director Kelly A. Kramer received new equity awards as compensation. On April 30, 2026, Kramer was granted a non-qualified stock option covering 4,884 shares of Gilead common stock at an exercise price of $130.84 per share, expiring in 2036, with all shares vesting immediately on the grant date.
On the same date, Kramer also received 1,146 restricted stock units, each representing the right to receive one share of Gilead common stock. These RSUs vested 100% immediately at grant. Following the RSU award, Kramer’s reported RSU holdings totaled 20,256 units. These are awards from the company, not open‑market purchases.
Gilead Sciences, Inc. held its 2026 annual stockholder meeting, where a quorum was reached with 1,130,179,690 of 1,241,222,013 entitled shares represented. Stockholders elected nine directors for one-year terms and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders approved, on an advisory basis, compensation for Named Executive Officers and also approved the amended and restated 2022 Equity Incentive Plan. Three stockholder proposals—calling for an independent Board Chair policy, a report on extended patent exclusivities and patient access, and a report on ESG and DEI compensation metrics—did not receive approval.
Gilead Sciences Inc reported a 13G filing showing 7.51% ownership represented by 93,327,127 shares. Vanguard Capital Management states it has sole dispositive power over 93,327,127 shares and sole voting power for 12,672,351 shares, and discloses affiliated investment divisions that exercise voting or dispositive authority.
Gilead Sciences Chairman & CEO Daniel O'Day sold 10,000 shares of common stock in open-market trades. The sales occurred on April 28, 2026 at prices around $128.79 and $130.01 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025. Following the sales, he continues to hold more than 600,000 shares of Gilead common stock directly.